Jennifer Nason, Global Chairman of Investment Banking, J.P. Morgan, to share insights on global capital markets and what that means for Australian biotech at AusBioInvest on October 30 in Melbourne.
Considered one of Australia’s most successful global business leaders and one of the most senior and influential women on Wall Street, Australian ex-pat Jennifer Nason will fly in from New York to share insights on global capital markets during a fireside chat at Australia’s premier life science investment event AusBioInvest 2023.
With the capital markets that Australian biotechs usually look to for investment severely impacted by post-pandemic macroeconomic turbulence, Jennifer Nason’s fireside chat will shed light on the latest shifts and trends in the global capital markets and what that means for the biotech sector both globally and in Australia.
The self-proclaimed “accidental banker”, Jennifer Nason has been with J.P. Morgan for 38 years having first joined the Melbourne, Australia office. Co-founding and chairing the Investment Banking Women’s Network at J.P. Morgan in the mid-1990s, today Jennifer is a Global Chair of the Investment Banking practice, sits on the Executive Committee of Investment Banking, and is responsible for many of the firm’s key investment banking relationships around the world.
Jennifer has advised on some of the world’s biggest deals in the tech and telecommunications sectors, such as Discovery’s $US43 billion buyout of Warner Media from AT&T, and Oracle’s $US20 billion capital raising in March last year. She also serves as a director of Rio Tinto, PLC FTSE 100 company and Chairs the American Australian Association’s Business Council.
Stepping onto the stage of, AusBioInvest 2023, delegates can hear the latest insights and trends in life science investing from global and local experts, and make meaningful connections with leading local biotech executives from publicly-listed and privately-owned companies as they pitch their breakthrough health innovations to investors.
Qualified investors are invited to register for their complimentary pass today and to hear from their peers as well as the latest from Australian innovators, including ESFAM Biotech, Imagion Biosystems, Invion, Cyban, Vaxxas, and Respiri which have joined the investee cohort. Delegates that do not fit within the Qualified Investor criteria are invited to register as an AusBioInvest 2023 delegate.
Register for AusBioInvest 2023 here.
